 | | Vol. 12.38 – 9 October, 2020 |
| |
|
|
| Scientists report that the key T helper 17 cell differentiation stimulator, STAT3, was subjected to reversible S-palmitoylation on cysteine 108. DHHC7 palmitoylated STAT3 and promoted its membrane recruitment and phosphorylation.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators describe an unexpected function of ST2+ regulatory T cells in suppressing the innate immune response in the lung to environmental allergens without altering the adaptive immune response.
[Nature Immunology] |
|
|
|
| Using whole-genome CRISPR screening in mice, the authors identified a triggering receptor expressed on myeloid cells family receptor, TREML4, as a key regulator of inflammation and immune cell death in sepsis.
[Nature Immunology] |
|
|
|
| The nanoscavenger anchors on the extracellular matrix sweet away the reactive oxygen species (ROS) from tumor microenvironment to relieve the immunosuppressive immunogenic cell death elicited by specific chemotherapy and prolonged the survival of T cells for personalized cancer immunotherapy.
[Nature Communications] |
|
|
|
| Researchers showed that Treg cell development was normal in mice with Foxp3-specific knockout of hypoxia-inducible factor 1α (HIF-1α) or HIF-2α.
[Nature Communications] |
|
|
|
| Scientists targeted epigenetic regulators in a pharmacological screen and discovered that the lysine‐specific histone demethylase 1A was required for merkel cell carcinoma growth in vitro and in vivo.
[EMBO Molecular Medicine] |
|
|
|
| Investigators showed that IL‐33 significantly prolonged islet allograft survival. IL‐33‐treated mice had elevated numbers of ILC2s and regulatory T cells.
[EMBO Molecular Medicine] |
|
|
|
| Researchers report an epigenetic mechanism contributing to the development of metabolic exhaustion in tumor-infiltrating lymphocytes. Environmental stress produces epigenome remodeling events within tumor-infiltrating lymphocytes resulting from loss of the histone methyltransferase EZH2.
[Cancer Research] |
|
|
|
| Upregulation of IL-33 instigated type-2 inflammation in the metastatic microenvironment, and mediated recruitment of eosinophils, neutrophils and inflammatory monocytes to lung metastases.
[Cancer Research] |
|
|
|
| The authors developed a ‘dual-CAR’ targeting two multiple myeloma-associated antigens and explored its safety and efficacy. To reduce the “off target” toxicity, they used the recognition of paired antigens that were co-expressed by the tumor, to induce efficient CAR T cell activation.
[Cancer Immunology Research] |
|
|
|
| Scientists defined an extended role for an effective immune response, not just in direct killing of tumor cells, but in widescale remodelling of the tumor microenvironment to favor loss of ECM, elimination of cancer stem cells, and propagation of adaptive immunity.
[Cancer Immunology Research] |
|
|
|
| Investigators explored the function of M2 macrophages-derived exosomes on the invasion and metastasis of esophageal cancer with the involvement of lncRNA AFAP1-AS1/microRNA-26a/activating transcription factor 2 axis.
[Molecular Therapy-Nucleic Acids] |
|
|
|
| Scientists elucidated the function and possible role of a novel lncRNA, called lncRNA-AK149641, in the mechanism of lipopolysaccharide-induced inflammatory response in P815 mast cells.
[Scientific Reports] |
|
|
|
| Scientists investigated the immunomodulatory role of a liposomal azithromycin formulation in a clinically relevant model to enhance its therapeutic potency and avoid off-target effects.
[Scientific Reports] |
|
|
|
|
| Cancer immunotherapy using immune-checkpoint blockade has displayed promising clinical effects, but prevalent antibody-based inhibitors face multiple challenges such as low response rate, acquired resistance, and adverse effects.
[Oncogene] |
|
|
|
|
| CreakyJoints® Español announced that the Bristol Myers Squibb Foundation has funded the “RA Hispanic Outreach Program,” a $1 million, two-year grant to improve relationships between Hispanic people living with rheumatoid arthritis and rheumatologists.
[CreakyJoints® Español (BusinessWire, Inc.)] |
|
|
|
| Alivio Therapeutics announced a $3.3 million US Department of Defense Technology/Therapeutic Development Award to advance its product candidate, ALV-304, for the treatment of inflammatory bowel disease. Alivio’s inflammation-targeting disease immunomodulation approach involves selectively restoring immune homeostasis at inflamed sites in the body, while having minimal impact on the rest of the body’s immune system.
[Alivio Therapeutics] |
|
|
|
|
| November 2 – November 3
Virtual |
|
|
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | Purdue University – West Lafayette, Indiana, United States |
|
|
|
| | STEMCELL Technologies – Flexible |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
| | Rheinische Friedrich-Wilhelms-Universität – Bonn, Germany |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
